Identification of Pyrrolo [2,3-b] Pyridine Derivatives as Novel JAK1 Inhibitors for the Treatment of Inflammatory Bowel Disease
Molecules · 25.06.2026 · 31 (13) · 2236
DOI: 10.3390/molecules31132236 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 25.06.2026. Verfasst von Shuai Wen und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Taizhou University, Taizhou 225300, China. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Janus Kinase 1, Pyridines, Protein Kinase Inhibitors. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nanjing Science and Technology Plan Project, Natural Science Foundation of the Jiangsu Higher Education Institutions of China, Taizhou Natural Science Foundation.
Abstract (Originalsprache)
Treatment of inflammatory bowel disease (IBD) remains a major medical challenge due to the lack of safe and effective therapeutic agents. JAK1 has been validated as a key therapeutic target that modulates the pathological progression of IBD. In this study, using tofacitinib as the lead compound, we adopted a scaffold growth strategy to design and synthesize a series of pyrrolo [2,3-b] pyridine derivatives as novel JAK1 inhibitors for the treatment of IBD. Among them, compound 15 exerted potent inhibitory activity against JAK1 with an IC50 value of 0.48 nM. Western blot results showed that compound 15 significantly inhibited LPS-induced STAT1/3 phosphorylation in RAW264.7 cells. In addition, 15 exhibited satisfactory metabolic stability and oral bioavailability. In the DSS-induced colitis model, 15 remarkably ameliorated inflammatory symptoms, promoted epithelial repair, and inhibited the production of pro-inflammatory cytokines such as TNF-α and IL-6. Therefore, compound 15 is regarded as a promising candidate for the treatment of IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Taizhou University, Taizhou 225300, China.
- Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.
- Nanjing Linkinovo Biological Technology Research Institute, Nanjing 211100, China.
ORCID-Profile: Zheng-Yu Jiang
Förderung
- Nanjing Science and Technology Plan Project
- Natural Science Foundation of the Jiangsu Higher Education Institutions of China
- Taizhou Natural Science Foundation
Zitieren
APA
Wen, S., Xiao, C., Du, L. M., Ji, J., Sha, H. K., Lin, S. X., Mou, Y., Sun, H., & Jiang, Z. Y. (2026). Identification of Pyrrolo [2,3-b] Pyridine Derivatives as Novel JAK1 Inhibitors for the Treatment of Inflammatory Bowel Disease. Molecules, 31(13), 2236. https://doi.org/10.3390/molecules31132236
Vancouver
Wen S, Xiao C, Du LM, Ji J, Sha HK, Lin SX, et al. Identification of Pyrrolo [2,3-b] Pyridine Derivatives as Novel JAK1 Inhibitors for the Treatment of Inflammatory Bowel Disease. Molecules. 2026;31(13):2236. doi:10.3390/molecules31132236
BibTeX
@article{Wen2026,
author = {Wen, Shuai and Xiao, Can and Du, Li-Min and Ji, Jing and Sha, Hong-Kai and Lin, Shun-Xin-Wang and Mou, Yi and Sun, Hao and Jiang, Zheng-Yu},
title = {Identification of Pyrrolo [2,3-b] Pyridine Derivatives as Novel JAK1 Inhibitors for the Treatment of Inflammatory Bowel Disease},
journal = {Molecules},
year = {2026},
volume = {31},
number = {13},
pages = {2236},
doi = {10.3390/molecules31132236}
}
EUVIMED